4Cell® CHO Platform CLD Service: Innovation Accelerating DNA To MCB To Generate High-Titer And High-Quality Cell Lines

By Sami Ullah, Juliana Bischof, Katrin Brosch, Martina Raasholm, and Kristin Thiele

Cell line development (CLD) stands as a pivotal stage in the production process of biopharmaceutical therapeutics such as monoclonal antibodies (mAbs), charting the course for the future success of a molecule. While the rapid and efficient identification and development of a high-producing, stable cell line have always been critical, the urgency of time-to-clinic escalated during the COVID-19 pandemic. Moreover, many platforms lack a reliable and efficient method for early identification of high producers in the CLD timeline.

This study aimed to implement a high-throughput technology for the single cell cloning step, supporting enhanced clone outgrowth, early prediction of high producers, and expedited clone expansion. Learn about the CLD workflow that enabled improved cell outgrowth, early recognition of high-producer clones, and a reduction in the CLD timeline to just 9 weeks.